How Brexit Reshaped Clinical Trial Regulation in the United Kingdom

The departure of the United Kingdom (UK) from the European Union (EU) has fundamentally altered the regulatory landscape for clinical trials. Before Brexit, the UK aligned with the EU Clinical Trials Directive (2001/20/EC) and prepared for full implementation of the EU Clinical Trial Regulation (CTR 536/2014). However, with Brexit taking effect in 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) assumed sole responsibility for clinical trial regulation in the UK, establishing independent frameworks and timelines. This shift has created both opportunities and challenges for sponsors, CROs, and investigators conducting research in the UK. Multi-country trials spanning both EU and UK jurisdictions now require dual submissions, with separate obligations under MHRA and EU regulators. Sponsors must navigate this dual compliance environment while adapting to evolving MHRA guidance, accelerated approval pathways, and inspection practices.

This article examines the impact of Brexit on UK clinical trial regulation, exploring key changes, implications for sponsors, and best practices for maintaining compliance in the post-Brexit era.

Background and Regulatory Framework

Pre-Brexit Alignment with the EU

Until 2020, the UK closely followed EU clinical trial directives and prepared for CTR 536/2014. Harmonization enabled single submissions for EU-wide trials, with MHRA acting in coordination with EMA.

Post-Brexit Transition

Brexit ended UK participation in EMA-led systems such as CTIS. MHRA assumed full oversight of UK CTAs, introducing its own processes through the Integrated Research Application System (IRAS) and UK-specific guidance.

UK Clinical Trials Consultation

In 2021–2022, MHRA launched consultations on reforming UK clinical trial regulation to modernize processes, enhance transparency, and align with global innovation trends.

Core Clinical Trial Insights: Brexit Impacts

1. Independent MHRA Oversight

MHRA became the sole regulatory authority for CTAs, pharmacovigilance, and inspections. This independence allows the UK to design streamlined processes, though it also means additional regulatory submissions for global trials.

2. Dual Submissions for Multi-Country Trials

Trials spanning the EU and UK must undergo separate submissions: CTIS for EU Member States and IRAS for the UK. Sponsors must adapt operational workflows to avoid delays.

3. Regulatory Timelines

While EU CTR mandates specific timelines for trial approvals, MHRA has introduced flexible approaches, including expedited reviews for public health emergencies (e.g., COVID-19 vaccines).

4. Transparency Obligations

The UK no longer participates in the EU CTIS transparency system but enforces trial registration and results disclosure through HRA and ISRCTN databases.

5. GCP Inspections

MHRA has strengthened its inspection regime, with a focus on data integrity, CRO oversight, and compliance with independent UK standards.

6. Divergence in Regulatory Pathways

While the EU has fully implemented CTR 536/2014, the UK is consulting on reforms that may diverge further, particularly in risk-based monitoring and decentralized trial adoption.

7. Sponsor Challenges

Sponsors face increased administrative burden from dual submissions, differing transparency requirements, and challenges in aligning pharmacovigilance across EU and UK systems.

8. CRO and Site Adaptation

CROs operating across EU and UK must maintain separate compliance infrastructures. NHS sites have adapted to independent MHRA inspections, with training and SOP updates.

9. Case Study: COVID-19 Trials

Brexit coincided with the COVID-19 pandemic, creating urgent demand for regulatory agility. MHRA introduced rolling reviews and expedited CTAs, showcasing its ability to act independently and rapidly.

Best Practices & Preventive Measures

• Develop dual regulatory strategies for EU and UK trials.
• Engage MHRA scientific advice early to address novel trial designs.
• Train investigators and CRO partners on independent UK transparency rules.
• Maintain harmonized SOPs covering EU CTR and MHRA guidance.
• Audit inspection readiness across both EU and UK systems.

Scientific and Regulatory Evidence

• Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
• MHRA Clinical Trials Guidance (2021–2023)
• EU Clinical Trial Regulation 536/2014
• ICH E6(R2) – Good Clinical Practice
• WHO Statement on Clinical Trial Transparency

Special Considerations

Brexit has unique implications across different trial categories:

• Oncology: Large-scale oncology trials must now manage dual submissions to EU and UK regulators.
• Rare Diseases: Small populations require cross-border collaboration, complicated by separate EU and UK requirements.
• Decentralized Trials: MHRA has been proactive in adopting digital and remote methodologies, diverging from some EU approaches.
• Pediatrics: Sponsors must meet independent UK ethics review processes in addition to EU Pediatric Investigation Plans (PIPs).

When Sponsors Should Seek Regulatory Advice

• When designing multi-country trials requiring both EU and UK approvals.
• Before implementing decentralized or adaptive trial designs in the UK.
• If uncertainty arises on divergent safety reporting obligations across EU and UK.
• When planning pharmacovigilance systems spanning EU and UK jurisdictions.
• If inspection findings reveal compliance gaps linked to Brexit changes.

FAQs

1. How has Brexit changed clinical trial submissions?

Sponsors must now submit separately to MHRA in the UK and CTIS in the EU, increasing administrative burden.

2. Does the UK still follow the EU CTR?

No. The UK is not bound by CTR 536/2014 but continues to adopt similar principles while consulting on its own reforms.

3. How does Brexit affect trial transparency?

The UK enforces its own transparency obligations via HRA and ISRCTN rather than CTIS.

4. What role does MHRA play post-Brexit?

MHRA is now the sole authority for CTAs, inspections, and safety reporting in the UK.

5. How are pharmacovigilance obligations managed?

Sponsors must ensure separate compliance with MHRA and EU pharmacovigilance requirements.

6. Are timelines different from the EU?

Yes. While EU CTR specifies timelines, MHRA has introduced flexible and expedited reviews, particularly for urgent public health needs.

7. What is the biggest sponsor challenge?

Managing dual submissions and divergent transparency requirements across EU and UK jurisdictions.

Conclusion

Brexit has reshaped clinical trial regulation in the UK, granting MHRA full independence while creating new compliance challenges for sponsors. Separate submissions, divergent transparency obligations, and dual pharmacovigilance requirements increase administrative complexity. However, MHRA’s agility, emphasis on innovation, and willingness to consult on reforms also present opportunities. Sponsors that adapt quickly, develop dual strategies, and engage proactively with MHRA will be best positioned to succeed in the evolving UK clinical research environment.